Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 27, 2021 at 04:04 am EDT
Share
Zhejiang Xinguang Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 96.123 million compared to CNY 70.769 million a year ago. Operating income was CNY 45.867 million compared to CNY 32.129 million a year ago. Net income was CNY 38.981 million compared to CNY 27.303 million a year ago. Basic earnings per share from continuing operations was CNY 0.24 compared to CNY 0.17 a year ago.
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of Chinese patent medicines, chemical medicines and health foods. The Company's main products are Huangqishengmaiyin, Shenjindan Capsules, American Ginseng Oral Liquid and other products. The treatment scope is mainly cardiovascular and cerebrovascular diseases, trauma diseases, and covers respiratory system, digestive system, urinary system, pediatric diseases and improving immunity. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.